Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein

Autores
Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.
Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; Argentina
Fil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; Francia
Materia
Inflammation
Drug repurposing
Rifampicin quinone
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/120529

id CONICETDig_cfb4ac468d4d809a9f2e7acc26141e2d
oai_identifier_str oai:ri.conicet.gov.ar:11336/120529
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synucleinAcuña, LeonardoCorbalan, Natalia SoledadRaisman Vozari, RitaInflammationDrug repurposingRifampicin quinonehttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; ArgentinaFil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; ArgentinaFil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; FranciaShenyang Editorial Dept Neural Regeneration Res2019-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/120529Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-14741673-5374CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.274336info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059564/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:16:39Zoai:ri.conicet.gov.ar:11336/120529instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:16:39.397CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
title Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
spellingShingle Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
Acuña, Leonardo
Inflammation
Drug repurposing
Rifampicin quinone
title_short Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
title_full Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
title_fullStr Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
title_full_unstemmed Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
title_sort Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
dc.creator.none.fl_str_mv Acuña, Leonardo
Corbalan, Natalia Soledad
Raisman Vozari, Rita
author Acuña, Leonardo
author_facet Acuña, Leonardo
Corbalan, Natalia Soledad
Raisman Vozari, Rita
author_role author
author2 Corbalan, Natalia Soledad
Raisman Vozari, Rita
author2_role author
author
dc.subject.none.fl_str_mv Inflammation
Drug repurposing
Rifampicin quinone
topic Inflammation
Drug repurposing
Rifampicin quinone
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.
Fil: Acuña, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Corbalan, Natalia Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta; Argentina. Universidad Nacional de Salta; Argentina
Fil: Raisman Vozari, Rita. Centre de Recherche de I'Institut du Cerveau et de la Moelle Epinière; Francia. Sorbonne University; Francia. Inserm; Francia
description The World Health Organization has predicted that neurodegenerative diseasesaffecting the motor function will become the second most prevalent cause ofdeath in the next 20 years. New therapies can result from three main sources:synthetic compounds, natural products, and existing drugs. Parkinson?s disease (PD) is a common neurodegenerative disease affecting 1?3% of the adult population over 50 years of age worldwide. It is initially characterized by the death of dopaminergic neurons in the substantia nigra pars compact and later by the widespread loss of nondopaminergic neurons, including those in the cortex (Goedert et al., 2013). Inflammation is the main underlying cause in most, if not all, neurodegenerative diseases, playing a protective role in their initial acute phases, but a pernicious one in their later chronic phases. Increasing evidence has disclosed that microglia-mediated neuroinflammation is crucial for PD progression (Hirsch and Hunot, 2009). Another neuropathological hallmark of PD is the presence of Lewy bodies, which are primarily composed of α-synuclein (α-Syn) aggregates (Goedert et al., 2013). In recent years, important studies on the role of α-Syn in PD have been conducted. The α-Syn aggregation in the central nervous system is a pathological process of fundamental importance in the development and progression of PD. Aggregates of α-Syn, in oligomeric and fibril forms, are thought to be capable of causing neurodegeneration either by directly damaging neurons or by activating microglia to produce neuroinflammatory mediators, which are neurotoxic (Hirsch and Hunot, 2009). Due to the consequent neuronal damage, an aggregation and release process of endogenous α-Syn occurs, triggering microglial activation and leading to neuroinflammation (Sanchez-Guajardo et al., 2015). In this way, α-Syn aggregates generate a vicious circle of neuroinflammation and neuronal death in PD. The interaction between these two players, α-Syn aggregates and microglial cells, is thus believed to be strongly implicated in the inflammatory process that accompanies PD progression. However, the molecular mechanisms that underlie α-Syn-induced microglia activation are not well understood.
publishDate 2019
dc.date.none.fl_str_mv 2019-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/120529
Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-1474
1673-5374
CONICET Digital
CONICET
url http://hdl.handle.net/11336/120529
identifier_str_mv Acuña, Leonardo; Corbalan, Natalia Soledad; Raisman Vozari, Rita; Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 15; 8; 12-2019; 1473-1474
1673-5374
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.274336
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059564/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Shenyang Editorial Dept Neural Regeneration Res
publisher.none.fl_str_mv Shenyang Editorial Dept Neural Regeneration Res
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842980907614470144
score 12.993085